131 related articles for article (PubMed ID: 21043990)
1. Atorvastatin attenuates inflammatory infiltration and vascular remodeling in lung of hypercholesterolemia rabbits.
Duan S; Zhang Y; Wu SJ; Jiang LZ; Zhang J; Gan Y; Chen P; Zhao SP; Li GY
Exp Lung Res; 2010 Dec; 36(10):573-92. PubMed ID: 21043990
[TBL] [Abstract][Full Text] [Related]
2. [Effect of atorvastatin on inflammatory infiltration in the lung of rabbits with hypercholesterolemia].
Wu S; Li G; Zhang J; Zhang Y; Gan Y; Xing X; Chen P; Zhao S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 34(7):608-15. PubMed ID: 19648672
[TBL] [Abstract][Full Text] [Related]
3. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
4. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response.
Boodhwani M; Nakai Y; Voisine P; Feng J; Li J; Mieno S; Ramlawi B; Bianchi C; Laham R; Sellke FW
Circulation; 2006 Jul; 114(1 Suppl):I402-8. PubMed ID: 16820608
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway.
Li J; Li JJ; He JG; Nan JL; Guo YL; Xiong CM
Cardiovasc Ther; 2010; 28(1):8-14. PubMed ID: 20074254
[TBL] [Abstract][Full Text] [Related]
6. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
7. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
8. Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation.
Lai WT; Lee KT; Chu CS; Voon WC; Yen HW; Tsai LY; Sheu SH
Int J Cardiol; 2005 Feb; 98(3):459-64. PubMed ID: 15708180
[TBL] [Abstract][Full Text] [Related]
9. Effects of Atorvastatin on some inflammatory parameters in severe primary hypercholesterolemia.
Dobreanu M; Gălăţeanu C; Simionescu A; Deac R
Rom J Intern Med; 2002; 40(1-4):61-73. PubMed ID: 15526541
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
11. Effect of atorvastatin on PM10-induced cytokine production by human alveolar macrophages and bronchial epithelial cells.
Sakamoto N; Hayashi S; Mukae H; Vincent R; Hogg JC; van Eeden SF
Int J Toxicol; 2009; 28(1):17-23. PubMed ID: 19482827
[TBL] [Abstract][Full Text] [Related]
12. Fluvastatin prevents renal injury and expression of lactin-like oxidized low-density lipoprotein receptor-1 in rabbits with hypercholesterolemia.
Yu YH; Wang Y; Dong B; Sun SZ; Chen Y; Meng XH; Liu ZZ
Chin Med J (Engl); 2005 Apr; 118(8):621-6. PubMed ID: 15899115
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
[TBL] [Abstract][Full Text] [Related]
14. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
15. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation.
Wissing KM; Unger P; Ghisdal L; Broeders N; Berkenboom G; Carpentier Y; Abramowicz D
Transplantation; 2006 Sep; 82(6):771-8. PubMed ID: 17006324
[TBL] [Abstract][Full Text] [Related]
16. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
Youssef S; Stüve O; Patarroyo JC; Ruiz PJ; Radosevich JL; Hur EM; Bravo M; Mitchell DJ; Sobel RA; Steinman L; Zamvil SS
Nature; 2002 Nov; 420(6911):78-84. PubMed ID: 12422218
[TBL] [Abstract][Full Text] [Related]
17. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
Goicoechea M; de Vinuesa SG; Lahera V; Cachofeiro V; Gómez-Campderá F; Vega A; Abad S; Luño J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
Sansanayudh N; Wongwiwatthananukit S; Putwai P; Dhumma-Upakorn R
Ann Pharmacother; 2010 Mar; 44(3):415-23. PubMed ID: 20179259
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors.
Chong PH; Seeger JD
Pharmacotherapy; 1997; 17(6):1157-77. PubMed ID: 9399600
[TBL] [Abstract][Full Text] [Related]
20. Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy.
Rosenblat M; Hayek T; Hussein K; Aviram M
Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):175-80. PubMed ID: 14592851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
